Abstract: A hot water supply system includes: a water heater; a circulating water passage; a water supply passage; and a circulating pump. The water heater is configured to emergently stop if a burner is performing combustion, an air supply fan is operating, the circulating pump is not operating, and a temperature detected by an apparatus interior temperature sensor exceeds an upper limit temperature. The water heater is configured to execute an apparatus interior cooling operation of stopping combustion of the burner, driving the air supply fan, and driving the circulating pump, if the burner is performing combustion, the air supply fan is operating, the circulating pump is operating, and the temperature detected by the apparatus interior temperature sensor exceeds the upper limit temperature.

Abstract: A hot water supply system includes: a water heater; a circulating water passage; a water supply passage; and a circulating pump. The water heater is configured to emergently stop if a burner is performing combustion, an air supply fan is operating, the circulating pump is not operating, and a temperature detected by an apparatus interior temperature sensor exceeds an upper limit temperature. The water heater is configured to execute an apparatus interior cooling operation of stopping combustion of the burner, driving the air supply fan, and driving the circulating pump, if the burner is performing combustion, the air supply fan is operating, the circulating pump is operating, and the temperature detected by the apparatus interior temperature sensor exceeds the upper limit temperature.

Abstract: The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

Abstract: A combustion control system includes: a memory section having stored therein each control data corresponding to each of the models; a switch input section designating setting contents of each model, the setting contents being set for each of the setting items relating to the operation by switched-on/switched-off state of each switch; and an instruction section which instructs the combustion control based on control. The switch input section is provided with at least two groups each being made up of a plurality of switches. An abnormality distinguishing section is provided to distinguish whether on-off states of one group of switches and on-off states of the other group of switches coincide with each other. When the on-off states are distinguished not to coincide with each other, an instruction is given to stop the combustion control. Incomplete combustion is thus prevented even at the time of failure or wrong operation of switches.

Abstract: Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

Abstract: A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

Abstract: Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

Abstract: Disclosed are DNA encoding a polypeptide which can modulate the activity of a muscle-specific tyrosine kinase, and others. The DNA is selected from the following members (a) to (d): (a) DNA comprising a specific nucleotide sequence; (b) DNA comprising a nucleotide sequence capable of hybridizing with a specific nucleotide sequence under stringent conditions; (c) DNA comprising a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or several amino acid residues in a specific amino acid sequence; and (d) DNA comprising a nucleotide sequence having 90% or higher homology to a specific nucleotide sequence.

Abstract: Disclosed are DNA encoding a polypeptide which can modulate the activity of a muscle-specific tyrosine kinase, and others. The DNA is selected from the following members (a) to (d): (a) DNA comprising a specific nucleotide sequence; (b) DNA comprising a nucleotide sequence capable of hybridizing with a specific nucleotide sequence under stringent conditions; (c) DNA comprising a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or several amino acid residues in a specific amino acid sequence; and (d) DNA comprising a nucleotide sequence having 90% or higher homology to a specific nucleotide sequence.